The IAS Severe FH Panel aimed to characterise the severe FH phenotype and make recommendations on how to stratify CVD risk and whom to prescribe the novel lipid-lowering treatments.
EAS 2016 European guidelines on cardiovascular disease prevention from the Sixth Joint Task Force provide up-to-date accessible recommendations for lipid control for clinicians in their routine practice.
ESC HF 2016 Adriaan Voors, ESC Heart Failure Guideline Task Force Co-Chairman summarises the most important changes in the 2016 guideline presented in Florence at the ESC Heart Failure Congress today, as compared with the 2012 guidelines.
ESC HF 2016 At the presentation of the new ESC Heart Failure Guidelines, Professor Ponikowski, Chairperson of the guidelines Task Force, summarised the guidelines as ten commandments.
ESC HF 2016 A new ESC HF guideline was presented at the ESC Heart Failure Congress in Florence, and includes a new definition of HF, and updated treatment algorithms for chronic and acute HF.
Paper gives guidance for discharge from emergency department or admission to hospital.
Leaders from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) and 36 National Heart Failure Societies formalised the promise by signing a Declaration.
European Society of Cardiology position paper outlines how the ESC will exploit e-health in education and research, while tackling issues of quality control and data security.
Consensus paper on optimal management of acute heart failure, benefitting from experience of various clinical settings involved, has been produced by three international societies.
Biomarkers can refine risk stratification and vascular biomarkers may be particularly informative as they integrate, predict risk and detect subclinical disease from different vascular beds.
The FDA has approved alirocumab injections, and the European EMA has recommended approval of this PCKS9-inhibitor as an adjunct to diet and other lipid-lowering drugs.
Evolocumab is the first PCSK9 inhibitor to be approved worldwide, which means a milestone for patients with uncontrolled cholesterol who require additional intensive LDL-C reduction.